On Jun. 28, 2025, Hikma Pharmaceuticals USA announced it will invest $1 billion by 2030 to further expand its US manufacturing and R&D capabilities.  This new phase of investment — America Leans on Hikma: Quality Medicines Manufactured in the USA – will further expand Hikma’s well-established domestic capabilities to develop, produce and deliver a broad range of medicines needed by the US healthcare system to treat patients nationwide.   

Hikma has operated in the U.S. since 1991 and has spent more than $4 billion over the past 15 years to build, enhance and expand its US-based R&D and manufacturing capabilities and now has annual domestic capacity to produce more than 12 billion finished doses of essential medicines. Over this period, Hikma has provided patients with access to a wide range of generic medicines at a lower cost than branded products.

America Leans on Hikma represents the Company’s latest efforts to increase the volume of essential medicines it develops and produces across its R&D and manufacturing sites in Columbus and Cleveland, Ohio and in Cherry Hill and Dayton, New Jersey. This next phase of expansion will help to strengthen Hikma’s portfolio of more than 800 medicines and increase the Company’s US-based capacity to produce large volumes of high-quality and affordable medicines for American hospitals, providers and patients.